AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35849009 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (3.5 g) of EPA + DHA
Number of subjects: 32
Study 35849009 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose (2.0 g) of EPA + DHA
Number of subjects: 32
Study 35849009 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 32
Study 33809740 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Feedback with Pedagogical Activity (VF‐PA)
Number of subjects: 35
Study 33809740 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Feedback (VF)
Number of subjects: 35
Study 33809740 — intervention group
Group type: COMPARATOR
Intervention: Control group (CONT)
Number of subjects: 35
Study 34254892 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behaviour therapy for perfectionism (ICBT-P)
Number of subjects: 89
Study 34254892 — intervention group
Group type: COMPARATOR
Intervention: Control group (access to treatment 8 weeks post-randomisation)
Number of subjects: 89
Study 33651735 — intervention group
Group type: EXPERIMENTAL
Intervention: Change of direction speed and technique modification training (2 sessions per week for 6 weeks)
Number of subjects: 27
Study 33651735 — intervention group
Group type: EXPERIMENTAL
Intervention: Change of direction speed and technique modification training
Number of subjects: 27
Study 33106863 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/Tazobactam
Number of subjects: 379
Study 33106863 — intervention group
Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 379
Study 32408589 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium cut-off membrane (Theranova)
Number of subjects: 5
Study 32408589 — intervention group
Group type: COMPARATOR
Intervention: High-flux membrane (Revaclear)
Number of subjects: 5
Study 35266378 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided serratus plane block (SPB) with 30 mL 0.25% bupivacaine
Number of subjects: 60
Study 35266378 — intervention group
Group type: COMPARATOR
Intervention: Control group received 2 mL saline injection subcutaneously
Number of subjects: 60
Study 33084881 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic ventral hernia repair
Number of subjects: 75
Study 33084881 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic ventral hernia repair
Number of subjects: 75
Study 34089046 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-fold increase in the Earned Income Tax Credit
Number of subjects: 5968
Study 34932077 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive therapeutic drug monitoring (TDM) with dose and interval adjustments based on scheduled monitoring of serum drug levels and antidrug antibodies (n=228)
Number of subjects: 458
Study 34932077 — intervention group
Group type: COMPARATOR
Intervention: Standard infliximab therapy without drug and antibody level monitoring (n=230)
Number of subjects: 458
Study 36173595 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum SPF 50 sunscreen (investigational product)
Number of subjects: 65
Study 36173595 — intervention group
Group type: COMPARATOR
Intervention: SPF 50+ (P8) reference product
Number of subjects: 65
Study 36173595 — intervention group
Group type: COMPARATOR
Intervention: SPF 30 (P5) reference product
Number of subjects: 65
Study 36173595 — intervention group
Group type: COMPARATOR
Intervention: SPF 15 (P3) reference product
Number of subjects: 65
Study 36173595 — intervention group
Group type: COMPARATOR
Intervention: Unprotected positive control area
Number of subjects: 65
Study 36173595 — intervention group
Group type: COMPARATOR
Intervention: Non-exposed negative control area
Number of subjects: 65
Study 32876654 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate coronary angiography and PCI if indicated
Number of subjects: 552
Study 32876654 — intervention group
Group type: COMPARATOR
Intervention: Delayed coronary angiography and PCI if indicated
Number of subjects: 552
Study 35121062 — intervention group
Group type: EXPERIMENTAL
Intervention: Yerba mate infusion (300 mL)
Number of subjects: 30
Study 35121062 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot tea (300 mL)
Number of subjects: 30
Study 35121062 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold tea (300 mL)
Number of subjects: 30
Study 35121062 — intervention group
Group type: COMPARATOR
Intervention: Comparison of hot tea and yerba mate infusion
Number of subjects: 30
Study 35121062 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 30
Study 35121062 — intervention group
Group type: COMPARATOR
Intervention: All subjects
Number of subjects: 30
Study 32813407 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care interventions
Number of subjects: 0
Study 32813407 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 32408846 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) for 8 weeks
Number of subjects: 93
Study 32408846 — intervention group
Group type: COMPARATOR
Intervention: Control group (single session of needs assessment, brief counseling/education, and referral)
Number of subjects: 93
Study 33427183 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3
Study 33427183 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster care
Number of subjects: 3
Study 33427183 — intervention group
Group type: EXPERIMENTAL
Intervention: Never-institutionalized
Number of subjects: 3
Study 36502333 — intervention group
Group type: EXPERIMENTAL
Intervention: M. officinalis extract (500 mg of RA per day)
Number of subjects: 323
Study 36502333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 323
Study 36502333 — intervention group
Group type: EXPERIMENTAL
Intervention: M. officinalis extract
Number of subjects: 323
Study 34161564 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain training
Number of subjects: 158
Study 34161564 — intervention group
Group type: COMPARATOR
Intervention: Control training
Number of subjects: 158
Study 35687394 — intervention group
Group type: EXPERIMENTAL
Intervention: OutsidePlay‐ECE risk‐reframing intervention
Number of subjects: 563
Study 35687394 — intervention group
Group type: COMPARATOR
Intervention: Position Statement on Active Outdoor Play (Control)
Number of subjects: 563
Study 34478124 — intervention group
Group type: EXPERIMENTAL
Intervention: Repository corticotropin injection (RCI; Acthar® Gel) 80 U subcutaneously every other day for 4 weeks and then twice weekly through week 24
Number of subjects: 0
Study 34478124 — intervention group
Group type: EXPERIMENTAL
Intervention: Repository corticotropin injection (RCI; Acthar® Gel)
Number of subjects: 0
Study 34478124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36141903 — intervention group
Group type: EXPERIMENTAL
Intervention: Flower arrangement with stocks and carnations
Number of subjects: 30
Study 36141903 — intervention group
Group type: EXPERIMENTAL
Intervention: Flower arrangement with lilies
Number of subjects: 30
Study 32559052 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementless tibial fixation
Number of subjects: 100
Study 32559052 — intervention group
Group type: COMPARATOR
Intervention: Cemented tibial fixation
Number of subjects: 100
Study 36369781 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided genicular nerve block (GNB) with 5.7 mg celestone chronodose (1 ml) and 0.5% bupivacaine (3 ml)
Number of subjects: 59
Study 36369781 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 59
Study 36369781 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided genicular nerve block (GNB)
Number of subjects: 59
Study 33517291 — intervention group
Group type: EXPERIMENTAL
Intervention: TissuGlu®
Number of subjects: 70
Study 33517291 — intervention group
Group type: COMPARATOR
Intervention: Drain
Number of subjects: 70
Study 35345271 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapeutic hypothermia (ETH) for 18 minutes at a target temperature of 32 ± 1.0 ◦C
Number of subjects: 50
Study 35345271 — intervention group
Group type: COMPARATOR
Intervention: PCI-only (control group)
Number of subjects: 50
Study 35345271 — intervention group
Group type: COMPARATOR
Intervention: Comparison of door-to-balloon time between ETH and control
Number of subjects: 50
Study 33952684 — intervention group
Group type: EXPERIMENTAL
Intervention: Obturator nerve block with 20 mL of ropivacaine 0.2%
Number of subjects: 60
Study 33952684 — intervention group
Group type: COMPARATOR
Intervention: Sham block (placebo group) with saline
Number of subjects: 60
Study 33952684 — intervention group
Group type: EXPERIMENTAL
Intervention: Obturator nerve block
Number of subjects: 60
Study 33952684 — intervention group
Group type: COMPARATOR
Intervention: Sham block (placebo group)
Number of subjects: 60
Study 32701129 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus radiotherapy (IMRT after chemotherapy)
Number of subjects: 126
Study 32701129 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 126
Study 34724405 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) intervention teaching pain self‐management skills in 12 weekly, 90‐minute groups delivered by an interdisciplinary team.
Number of subjects: 850
Study 34724405 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) intervention
Number of subjects: 850
Study 34724405 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 850
Study 34553395 — intervention group
Group type: EXPERIMENTAL
Intervention: GSH-FBT (online guided self-help family-based treatment) for parents, 12 sessions of 20 minutes each
Number of subjects: 40
Study 34553395 — intervention group
Group type: COMPARATOR
Intervention: FBT-V (family-based treatment delivered via videoconferencing), 15 sessions of 60 minutes each
Number of subjects: 40
Study 34553395 — intervention group
Group type: EXPERIMENTAL
Intervention: GSH-FBT
Number of subjects: 40
Study 34553395 — intervention group
Group type: COMPARATOR
Intervention: FBT-V
Number of subjects: 40
Study 33067703 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC5) and bevacizumab (10 mg/kg) every 3 weeks
Number of subjects: 73
Study 34774015 — intervention group
Group type: EXPERIMENTAL
Intervention: ASICA intervention
Number of subjects: 121
Study 33198867 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔP guided sedation strategy
Number of subjects: 60
Study 33198867 — intervention group
Group type: COMPARATOR
Intervention: Light sedation strategy
Number of subjects: 60
Study 34378159 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic postconditioning (RIPostC)
Number of subjects: 70
Study 34378159 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study 33941150 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical-lesion group (106 patients)
Number of subjects: 185
Study 33941150 — intervention group
Group type: COMPARATOR
Intervention: Non-cervical-lesion group (79 patients)
Number of subjects: 185
Study 35522237 — intervention group
Group type: EXPERIMENTAL
Intervention: Optional Results Choice Aid (ORCA)
Number of subjects: 231
Study 35522237 — intervention group
Group type: COMPARATOR
Intervention: Web-based additional findings information
Number of subjects: 231
Study 33063541 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegan multi-ingredient (VGMT)
Number of subjects: 10
Study 33063541 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (MALT)
Number of subjects: 10
Study 35610297 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial activity tracker bracelet with daily activity goal and inactivity alerts for 12 months
Number of subjects: 231
Study 35610297 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 231
Study 616774613 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic concurrent therapy
Number of subjects: 60
Study 616774613 — intervention group
Group type: COMPARATOR
Intervention: Sequential therapy (Control)
Number of subjects: 60
Study 35860947 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful eating intervention
Number of subjects: 55
Study 35860947 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful eating + planning intervention
Number of subjects: 55
Study 35274723 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin
Number of subjects: 0
Study 32463470 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (150 mg for 4 weeks plus 300 mg for 8 weeks)
Number of subjects: 108
Study 32463470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 32463470 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 108
Study 36280809 — intervention group
Group type: EXPERIMENTAL
Intervention: ECD program (parenting training sessions and home-based training)
Number of subjects: 18
Study 36280809 — intervention group
Group type: EXPERIMENTAL
Intervention: ECD program with monthly developmental feedback
Number of subjects: 18
Study 36280809 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 18
Study 34147335 — intervention group
Group type: EXPERIMENTAL
Intervention: K‐K9 group (acupressure with Black Pepper Seed)
Number of subjects: 103
Study 34147335 — intervention group
Group type: EXPERIMENTAL
Intervention: P6 group (acupressure with wristband)
Number of subjects: 103
Study 34147335 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 103
Study 34600346 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 2 frozen embryo transfer (group A)
Number of subjects: 72
Study 34600346 — intervention group
Group type: COMPARATOR
Intervention: Overnight day 3 frozen embryo transfer (group B)
Number of subjects: 72
Study 34415794 — intervention group
Group type: COMPARATOR
Intervention: Tasking conditions (verbal, tactile) during rotary chair testing
Number of subjects: 20
Study 34415794 — intervention group
Group type: COMPARATOR
Intervention: No tasking condition
Number of subjects: 20
Study 34415794 — intervention group
Group type: EXPERIMENTAL
Intervention: Different types of tasking (verbal, tactile)
Number of subjects: 20
Study 34415794 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental or tactile tasking
Number of subjects: 20
Study 34415794 — intervention group
Group type: EXPERIMENTAL
Intervention: Braiding tactile task
Number of subjects: 20
Study 34415794 — intervention group
Group type: COMPARATOR
Intervention: Caloric testing
Number of subjects: 20
Study 33109254 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth technology plus centralised remote support
Number of subjects: 51
Study 33109254 — intervention group
Group type: COMPARATOR
Intervention: Telehealth technology alone
Number of subjects: 51
Study 36104012 — intervention group
Group type: EXPERIMENTAL
Intervention: Domagrozumab
Number of subjects: 0
Study 33169672 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab (70 mg every 4 weeks, 210 mg every 4 weeks, or 280 mg every 2 weeks)
Number of subjects: 550
Study 33169672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 550
Study 33169672 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Number of subjects: 550
Study 32103903 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan disodium 0.5 g
Number of subjects: 0
Study 32103903 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan disodium 1.0 g
Number of subjects: 0
Study 32103903 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan disodium 2.0 g
Number of subjects: 0
Study 32103903 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan disodium 1.0 g BID for 7 days
Number of subjects: 0
Study 32915004 — intervention group
Group type: EXPERIMENTAL
Intervention: Gratitude intervention (10 min of gratitude writing per week for 4 weeks)
Number of subjects: 1000
Study 32915004 — intervention group
Group type: COMPARATOR
Intervention: Control (listing daily activities and reflecting on obstacles and benefits)
Number of subjects: 1000
Study 35381421 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine infusion at 25 µg/min
Number of subjects: 150
Study 35381421 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion (Control)
Number of subjects: 150
Study 35129606 — intervention group
Group type: EXPERIMENTAL
Intervention: KeySteps@JC Parent‐Child Interaction program
Number of subjects: 267
Study 34152206 — intervention group
Group type: EXPERIMENTAL
Intervention: Conidial suspension (106 conidia mL‐1) of Fusarium oxysporum isolates, applied by pouring 50 ml per pot.
Number of subjects: 6
Study 34152206 — intervention group
Group type: COMPARATOR
Intervention: Sterile distilled water (control) applied by pouring 50 ml per pot.
Number of subjects: 6
Study 32939893 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 month lifestyle intervention
Number of subjects: 90
Study 33993273 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (β‐lactam plus aminoglycoside or quinolone)
Number of subjects: 1119
Study 33993273 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (β‐lactam)
Number of subjects: 1119
Study 33993273 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 1119
Study 32667636 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting aripiprazole monohydrate (AOM)
Number of subjects: 489
Study 32667636 — intervention group
Group type: COMPARATOR
Intervention: Usual care (clinician's choice, CC)
Number of subjects: 489
Study 34126275 — intervention group
Group type: EXPERIMENTAL
Intervention: StreetBit app (active alerts for 3 weeks)
Number of subjects: 385
Study 34126275 — intervention group
Group type: COMPARATOR
Intervention: StreetBit app (inactive for 3 weeks)
Number of subjects: 385
Study 34126275 — intervention group
Group type: COMPARATOR
Intervention: StreetBit app (inactive for 4 weeks post-intervention)
Number of subjects: 385
Study 32923335 — intervention group
Group type: EXPERIMENTAL
Intervention: Expository classes (G1)
Number of subjects: 1301
Study 32923335 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-based worked examples (G2)
Number of subjects: 1301
Study 35765103 — intervention group
Group type: EXPERIMENTAL
Intervention: UC-MSCs (1 × [Formula: see text] cells/kg BW per injection) every other day for three injections
Number of subjects: 20
Study 35765103 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 20
Study 33237361 — intervention group
Group type: EXPERIMENTAL
Intervention: tACS (transcranial alternating current stimulation)
Number of subjects: 15
Study 33237361 — intervention group
Group type: COMPARATOR
Intervention: RNS (random noise stimulation)
Number of subjects: 15
Study 36455606 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mm Hg elastic compression stockings (ECS)
Number of subjects: 341
Study 36455606 — intervention group
Group type: COMPARATOR
Intervention: 35 mm Hg elastic compression stockings (ECS)
Number of subjects: 341
Study 33176886 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate at 4 mmol/L associated with unfractionated heparin at 10 U/Kg/h (Group B)
Number of subjects: 90
Study 33176886 — intervention group
Group type: COMPARATOR
Intervention: Sodium citrate at 4 mmol/L (Group A - control)
Number of subjects: 90
Study 35485381 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg subcutaneously plus standard of care (group A)
Number of subjects: 50
Study 35485381 — intervention group
Group type: COMPARATOR
Intervention: Standard of care alone (group B)
Number of subjects: 50
Study 35485381 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg subcutaneously (group A)
Number of subjects: 50
Study 35485381 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab (group A)
Number of subjects: 50
Study 35485381 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (group B)
Number of subjects: 50
Study 33538248 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily plus aspirin 100 mg/day
Number of subjects: 27395
Study 35678785 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum and neem oil dressing (1PWD)
Number of subjects: 99
Study 35678785 — intervention group
Group type: COMPARATOR
Intervention: Silver-based dressings
Number of subjects: 99
Study 34849423 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone navigation to reduce financial strain and address social needs
Number of subjects: 1944
Study 34849423 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized tobacco quitline designed for low-income smokers
Number of subjects: 1944
Study 34849423 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1944
Study 32219884 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind, placebo-controlled oral food challenges (DBPCFC)
Number of subjects: 6105
Study 32219884 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental report of adverse reactions after food consumption
Number of subjects: 6105
Study 32219884 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick testing (SPT)
Number of subjects: 6105
Study 32219884 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prevalence estimates for food allergy (FA)
Number of subjects: 6105
Study 35029306 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab plus docetaxel
Number of subjects: 0
Study 35029306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32498755 — intervention group
Group type: EXPERIMENTAL
Intervention: F‐PROT + MPT (n 21)
Number of subjects: 60
Study 32498755 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐PROT + MPT (n 20)
Number of subjects: 60
Study 32498755 — intervention group
Group type: COMPARATOR
Intervention: Placebo + MPT (PLA; n 19)
Number of subjects: 60
Study 33424840 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFNα‐2b therapy
Number of subjects: 0
Study 33424840 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti‐CD24 antibody treatment
Number of subjects: 0
Study 33424840 — intervention group
Group type: EXPERIMENTAL
Intervention: Low induced CD24+CD38hi B cells
Number of subjects: 0
Study 34392115 — intervention group
Group type: EXPERIMENTAL
Intervention: EASE intervention delivered by adult refugees without prior training in mental health
Number of subjects: 146
Study 34392115 — intervention group
Group type: COMPARATOR
Intervention: Enhanced control condition
Number of subjects: 146
Study 32073648 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivantinib (360 mg twice daily) plus Cetuximab (500 mg/m2 every 2 weeks)
Number of subjects: 78
Study 32073648 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab (500 mg/m2 every 2 weeks)
Number of subjects: 78